IOVANCE BIOTHERAPEUTICS, INC. 8-K

What Happened
Iovance Biotherapeutics, Inc. filed a Form 8‑K (filed July 2, 2026) reporting that on June 30, 2026 the company updated its corporate presentation. The updated deck — titled "Corporate Presentation – June 2026" — is attached to the filing as Exhibit 99.1 and is incorporated by reference. The company said it intends to use the presentation at healthcare conferences and in communications with analysts, current stockholders and others.

Key Details

• Update date: June 30, 2026; Form 8‑K filed July 2, 2026.
• Exhibit attached: Exhibit 99.1 — "Iovance Biotherapeutics, Inc., Corporate Presentation – June 2026."
• Intended use: presentations at healthcare conferences and to analysts, current stockholders and other audiences.

Why It Matters
An updated corporate presentation is the company’s current public messaging tool; it may include refreshed program highlights, timelines, clinical data summaries or strategic priorities. Retail investors should review Exhibit 99.1 in the 8‑K to see any changes in how Iovance describes its clinical programs, milestones or investor guidance. The filing itself does not disclose other material corporate actions.